3,289 press releases indexed under healthcare.
Doha, Qatar – , 2026-07-15 — /EPR Network/ — First Vet is happy to offer trusted Veterinary Lab Testing in Doha for pets. The clinic [read full press release...]
Tokyo, Japan and Cambridge and London, UK, 15 July 2026 – Nxera Pharma Co. Ltd (“Nxera”; TSE 4565) will announce its earnings results and present operational highlights for 2Q 2026 on Friday, 7 August 2026. The Company will host a live webinar presentation with Chris Cargill (President, CEO), Hironoshin Nomura (CFO), Toshi Maeda (COO) and Patrik Foerch (CSO and President of Nxera Pharma UK), at 5:00 pm JST (9:00 am GMT) on Friday, 7 August 2026. The webinar is open to all existing and potential investors as well as sell-/buy-side analysts and will consist of a presentation followed by a Q&A session. Please click here to pre-register, which will provide a link to access the webinar. Presentation slides will be made available by 4:30 pm JST (8:30 am GMT) on 7 August 2026 through the inve
Across three independent studies, the NeuLogiq® Platform two-minute tablet-based Symbol Swap task delivered clinically meaningful discrimination between control, MCI and Alzheimer's dementia groups and detected blood-biomarker-defined pathology — including in clinically normal individuals...
Research Highlights: In an analysis of the Global Burden of Disease Study compared with U.S. Census data from 1990-2021, researchers found that people with congenital heart disease living in states with lower average household incomes and fewer people with health insurance had higher rates of death and disability. The research authors hypothesize that this difference may be due to easier access to specialized care and treatment from adult congenital heart disease cardiologists in communities with higher income levels and more residents with health insurance. Congenital heart disease requires lifelong, regular access to specialized cardiac care. Expanding access to expert care, particularly in under-resourced regions of the U.S., could play a profound role in improving survival and quality
Norwalk, USA, 2026-07-15 — /EPR Network/ — Beautiful skin is more than a trend. It is a reflection of healthy care and self-confidence. Lzur Day [read full press release...]
Dr. David B. Hardin of Noblesville, Indiana has been named Professional of the Year for Healthcare, Rehabilitation, and Wound Care by Strathmore's Who's Who Worldwide for his outstanding contributions and achievements in his field. About Dr. David B. Hardin Dr. David B. Hardin is a physician serving patients through his medical practice in Indiana, offering patient care and related services. With more than four decades [PR.com]
Research collaboration highlights safe surgical outcomes and significant health improvements in young patients in Louisiana [PR.com]
Continuous smartwatch monitoring shown to safely support post-surgical care, reducing disruptions for patients and easing nursing time for direct patient care SINGAPORE, July 14, 2026 /PRNewswire/ -- The National University Hospital (NUH) is set to expand the use of wearable technology...
Der Bericht hebt saubere Energie, Innovation und ESG-Anerkennung hervor ZIBO, China, 15. Juli 2026 /PRNewswire/ -- INTCO Medical („das Unternehmen"), ein weltweit führender Hersteller von Einweghandschuhen, hat seinen ESG-Bericht (Umwelt, Soziales und Unternehmensführung) für 2025...
Basel, 15 July 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today that the US Food and Drug Administration (FDA) has granted Priority Review to the company’s supplemental Biologics License Application (sBLA) for Gazyva®/Gazyvaro® (obinutuzumab) for the treatment of primary membranous nephropathy (pMN). The priority review is based on the positive phase III MAJESTY results, which show superiority of Gazyva/Gazyvaro over an immunosuppressive therapy, tacrolimus, in adults with pMN. 1 The FDA has already granted Breakthrough Therapy Designation (BTD) to Gazyva/Gazyvaro in pMN and is expected to make a decision on approval by November 2026. This is the second indication in recent months for which the US FDA has granted priority review to Gazyva/Gazyvaro, following idiopathic nephrotic s
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., July 15, 2026 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a novel class of custom-built protein drugs known as DARPin therapeutics (“Molecular Partners” or the “Company”), today highlights its approaches to overcoming target limitations in radioligand therapy (RLT) through Radio-DARPins, in a presentation at the Gordon Research Conference Radionuclide Theranostics for the Management of Cancer in Newry, Maine, US.
This Gorgeous Grandma Day, Lake Park Dental in Milwaukee spotlights how modern, metal-free implants help women 55 and up smile with confidence again. The post Lake Park Dental Celebrates Gorgeous Grandma Day With a Toast to Milwaukee Smiles first appeared on